RESUMO
Improvement in the sensitivity and specificity of UMELISA techniques as a result of the introduction of monoclonal antibodies superseding the use of polyclonal antibodies was studied. For this purpose, we performed a comparison of the results in the functioning of the screening programs before and after the introduction of monoclonal antibodies. We analyzed some parameters such as sensitivity, specificity and detection limit in the UMELISA HBsAg PLUS and UMELISA TSH techniques. The sensitivity and specificity parameters were evaluated by means of comparison with the commercial assays. The detection limit was calculated as the fluorescence of the calibrator 0 + 2 standard deviations. Since the introduction of MAb obtained for us an increase in the sensitivity, specificity, and positive predictive value was evidenced. On the other hand, the use of the MAb guarantees better stability in the diagnostic kit production process.